Venous and pulmonary thromboembolism and combined hormonal contraceptives. Systematic review and meta-analysis

European Journal of Contraception and Reproductive Health Care

Volumn 17, Issue 1, 2012, Pages 7-29

  Martínez, Francisca ^a   Ramrez, Isabel ^b   Pérez Campos, Ezequiel ^c   Latorre, Kepa ^d   Lete, Iaki ^e  

^a INSTITUT UNIVERSITARI DEXEUS   (Spain)

^b Servicio de Salud Sexual y Reproductiva   (Spain)

^c HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^d Unidad de Investigacion de Atencion Primaria de Bizkaia   (Spain)

^e Hospital Santiago   (Spain)

Author keywords

Combined hormonal contraception; Cyproterone acetate; Desogestrel; Drospirenone; Ethinylestradiol; Gestodene; Levonorgestrel; Norelgestromin; Norgestimate; Oral contraceptives; Transdermal contraceptive patch; Vaginal contraceptive ring; Venous thromboembolism

Indexed keywords

ANTICOAGULANT AGENT; CONTRACEPTIVE AGENT; CYPROTERONE ACETATE; DESOGESTREL; DROSPIRENONE; GESTAGEN; GESTODENE; LEVONORGESTREL; NORGESTIMATE; ORAL CONTRACEPTIVE AGENT;

DRUG DOSAGE FORM COMPARISON; HUMAN; LUNG EMBOLISM; META ANALYSIS; NONHUMAN; PRIORITY JOURNAL; REVIEW; SYSTEMATIC REVIEW; VENOUS THROMBOEMBOLISM;

CONTRACEPTIVE DEVICES, FEMALE; CONTRACEPTIVES, ORAL, COMBINED; CONTRACEPTIVES, ORAL, HORMONAL; HUMANS; PULMONARY EMBOLISM; VENOUS THROMBOEMBOLISM;

EID: 84855844752     PISSN: 13625187     EISSN: 14730782     Source Type: Journal    
DOI: 10.3109/13625187.2011.643836     Document Type: Review

References (71)

1. Martinelli I. Counseling women about hormonal therapy. Thromb Res 2009;123(Suppl. 2):574-8.
2. Blanco-Molina A, Trujillo-Santos J, Tirado R, e t al. Venous thromboembolism in women using hormonal contraceptives. Findings from the RIETE Registry. Thromb Haemost 2009;101:478-82.
3. Heinemann LA, Dinger JC. Range of published estimates of venous thromboembolism incidence in young women. Contraception 2007;75:328-36. (Pubitemid 46551070)
4. Dinger JC , Heinemann LAJ, Kü l-Habich D. The safety of a drospirenone-containing oral contraceptive: fi nal results from the European Active Surveillance study on Oral Contraceptives based on 142,475 women-years of observation. Contraception 2007;72: 344-54. (Pubitemid 46551071)
5. Vessey M, Painter R, Yeates D. Mortality in relation to oral contraceptive use and cigarette smoking. Lancet 2003;362:185-91. (Pubitemid 36859933)
6. Colditz GA. Oral contraceptive use and mortality during 12 years of follow-up: The NursesHealth Study. Ann Intern Med 1994;120:821-6. (Pubitemid 24140507)
7. Beral V, Hermon C, Kay C, e t al. Mortality associated with oral contraceptive use: 25 year follow-up cohort of 46 000 women from Royal College of General Practitionersoral contraception study. BMJ 1999;318:96-100. (Pubitemid 29188927)
8. Hannaford PC, Iversen L, Macfarlane TV, e t al. Mortality among contraceptive pill users: cohort evidence from Royal College of General PractitionersOral Contraception Study. BMJ 2010;340:c927. doi: 10.1136/ bmj.c927.
9. Jick H, Kaye IA, Vasilakis-Scaramozza C, Jick SS. Risk of venous thromboembolism among users of thirdgeneration oral contraceptives compared with users of oral contraceptives with levonorgestrel before and after 1995: cohort and case-control analysis. BMJ 2000;321: 1190-5.
10. Farley TMM, Meirik O, Chang CL, e t al. Effect of different progestagens in low oestrogen oral contraceptives on venous thromboembolic disease. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Lancet 1995;346:1582-8. (Pubitemid 26001839)
11. Kemmeren IM, Algra A, Grobee DE. Third generation oral contraceptives and risk of venous thrombosis: metaanalysis. BMJ 2001;323:1-7.
12. World Health Organization. Cardiovascular disease and use of oral and injectable contraceptives. Contraception 1998;57:315-24.
13. World Health Organization. Medical eligibility criteria for contraceptive use, 4th edn. Geneva: WHO 2008, RHRH/08.19.
14. Jick SS, Kaye JA, Russmann S, Jick H. Risk of nonfatal venous thromboembolism with oral contraceptives containing norgestimate or desogestrel compared with oral contraceptives containing levonorgestrel. Contraception 2006;73:566-70.
15. Cole JA, Norman H, Doherthy M, Walker AM. Venous thromboembolism, myocardial infarction, and stroke among transdermal contraceptive system users. Obstet Gynecol 2007;109:339-46. (Pubitemid 46197426)
16. Stroup DF, Berlin JA, Morton SC, e t al. Meta-analysis of observational studies in epidemiology. A proposal for reporting. JAMA 2000;283:2008-12. (Pubitemid 30214957)
17. Jovell A, Navarro-Rubio MD. Evaluació n de la evidencia cient í fi ca. Med Cl í n 1995;105:740-3.
18. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7:177-88. (Pubitemid 17189972)
19. Galbraith R. A note on graphical presentation of estimated odds ratios from several clinical trials. Stat Med 1988;7:889-94.
20. Greenland S, Longnecker MP. Methods for trend estimation from summarized dose-response data, with applications to meta-analysis. Am J Epidemiol 1992; 135:1301-9.
21. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994;50:1088-101.
22. Bloemenkamp KWM, Rosendaal FR, Helmerhorst FM, et al Enhancement by factor V Leiden mutation of risk of deep venous thrombosis associated with oral contraceptives containing third-generation progestogen. Lancet 1995;346:1593-6. (Pubitemid 26001841)
23. Bloemenkamp KW, Rosendaal FR, Buller HR, e t al. Risk of venous thrombosis with use of current low-dose oral contraceptives is not explained by diagnostic suspicion and referral bias. Arch Int Med 1999;159:65-70. (Pubitemid 29044121)
24. Farmer RD, Lawrenson RA, Todd JC, e t al. Oral contraceptives and venous thromboembolic disease. Analyses of the UK General Practice Research Database and the UK MediPIus Database. Hum Reprod Update 1999;5:688-706 (Pubitemid 30034892)
25. Farmer RD, Lawrenson RA, Todd IC, et al. A comparison of the risks of venous thromboembolism disease in association with different combined oral contraceptives. Br J Pharmacol 2000;49:580-90. (Pubitemid 30326558)
26. Jick H, Jick SS, Gwewich K, e t al. Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components. Lancet 1995;346:1589-93. (Pubitemid 26001840)
27. Jick SS, Kaye JA, Russmann S, Jick H. Risk of nonfatal venous thromboembolism in women using a contraceptive transdermal patch and oral contraceptives containing norgestimate and 35 microg of ethinyl estradiol. Contraception 2006;73:223-8. (Pubitemid 43202170)
28. Jick SS, Kaye JA, Li L, Jick H. Further results on the risk of nonfatal venous thromboembolism in users of the contraceptive transdermal patch compared to users of oral contraceptives containing norgestimate and 35 g of ethinyl estradiol. Contraception 2007;76:4-7. (Pubitemid 46935110)
29. Lidegaard O. The infl uence of thrombotic risk factors when oral contraceptives are prescribed. A control-only study. Acta Obstet Gynecol Scand 1998;76:252-60. (Pubitemid 27122533)
30. Lidegaard O, Edstrom B, Kreiner S. Oral contraceptives and venous thromboembolism: A fi ve year national asecontrol study. Contraception 2002;65:187-96. (Pubitemid 34258539)
31. Parkin L, Skegg DC, Wilson M, et al. Oral contraceptives and fatal pulmonary embolism. Lancet 2000;355: 2133-4. (Pubitemid 30364664)
32. Seaman HE, de Vries CS, Farmer RD. Venous thromboembolism associated with cyproterone acetate in combination with ethinyloestradiol (Dianette): observational studies using the UK General Practice Research Database. Pharmacoepidemiol Drug Saf 2004;13:427-36. (Pubitemid 38996853)
33. Spitzer WO, Lewis MA, Heinemann LA, e t al. Third generation oral contraceptives and risk of venous hromboembolic disorders: An international case-control study. Transnational Research Group on Oral Contraceptives and the Health of Young Women. BMJ 1996;312:83-8.
34. van Hylckama Vlieg A, Helmerhost FM, Vandenbroucke JP, et al The venous thrombotic risk of oral contraceptives, effects of oestrogen dose and progestogen type: Results of the MEGA case-control study. BMJ 2009; 339b2921 doi:10.1136/bmj.b2921.
35. Vasilakis-Scaramozza C, Jick H. Risk of venous thromboembolism with cyproterone or levonorgestrel contraceptives. Lancet 2001;358:1427-9. (Pubitemid 33055749)
36. Poulter NR, Chang CL, Farley TMM, e t al. Venous thromboembolic disease and combined oral contraceptives: Results of international multicentre case-control study. World Health Organisation Collaborative study of Cardiovascular Diseases and Steroid Hormone Contraception. Lancet 1995;346:1575-82. (Pubitemid 26001838)
37. Farmer RD, Lawrenson RA, Thompson CR, e t al. Population based study of risk of venous thromboembolism associated with various oral contraceptives. Lancet 1997;349:83-8. (Pubitemid 27023424)
38. Hedenmalm K, Samuelsson E, Spigset O. Pulmonary embolism associated with combined oral contraceptives: Reporting incidences and potential risk factors for fatal outcome. Acta Obstet Gynecol Scand 2004;83:576-85. (Pubitemid 38703553)
39. Herings RM, Urquhart J, Leufkens HG. Risk of venous thromboembolism among users of different oral contraceptives. Lancet 1999;354:127-8. (Pubitemid 29313151)
40. Jick SS, Hernandez RK. Risk of non-fatal venous thromboembolism in women using oral contraceptives containing drospirenone compared with women using oral contraceptives containing levonorgestrel: case-control study using United States claims data. BMJ 2011; 340:d2151. doi:10.1136/bmj.d2151.
41. Lidegaard Ø, L økkegaard E, Svendsen AL, Agger C. Hormonal contraception and risk of venous thromboembolism: national follow-up study. BMJ 2009;339: b2890. doi: 10.1136/bmj.b2890.
42. Parkin L, Sharples K, Hernandez RK, Jick JS. Risk of venous thromboembolism in users of oral contraceptives containing drospirenone or levonorgestrel: nested casecontrol study based on UK General Practice Research Database. BMJ 2011;340:d2139. doi:10.1136/bmj.d2139.
43. Winkler UH. Haemostatic effects of third- and secondgeneration oral contraceptives: Absence of a causal mechanism for a difference in risk of venous thromboembolism. Contraception 2000;62:11S - 20S.
44. Kemmeren JM, Algra A, Meijers JCM, e t al. Effect of second- and third-generation oral contraceptives on the protein C system in the absence or presence of the factor V Leyden mutation: A randomized trial. Blood 2004; 103:927-33. (Pubitemid 38129552)
45. Tans G, Van Hylckama Vlieg A, Thomassen MCLGD, et al Activated protein C resistance determined with a thrombin generation-based test predicts for venous thrombosis in men and women. Br J Haematol 2003;122: 465-70. (Pubitemid 36951632)
46. van Vliet H, Winkel TA, Noort I, e t al. Prothrombotic changes in users of combined oral contraceptives containing drospirenone and cyproterone acetate. J Thromb Haemost 2004;2:2060-2. (Pubitemid 40192767)
47. van Vliet H, Frolich M, Christella M, e t al. Association between sex hormone-binding globulin levels and activated protein C resistance in explaining the risk of thrombosis in users of oral contraceptives containing different progestogens. Hum Reprod 2005;20:563-8. (Pubitemid 40277633)
48. Pomp ER, Le Cessie S, Rosendaal FR, Doggen CJ. Risk of venous thrombosis: obesity and its joint effect with oral contraceptive use and prothrombotic mutations. Br J Haematol 2007;139:289-96. (Pubitemid 47493087)
49. The European Agency for the Evaluation of Medical Products. CPMP Public assessment report: Combined oral contraceptives and venous thromboembolism. Doc. Ref: EMEA/CPMP/2201/01/en/Final
50. James AH, Jamison MG, Brancazio LR, Myers ER. Venous thromboembolism during pregnancy and the postpartum period: Incidence, risk factors, and mortality. Am J Obstet Gynecol 2006;194:1311-5.
51. Heinemann LA, Dinger JC, Assmann A, Minh TD. Use of oral contraceptives containing gestodene and risk of venous thromboembolism: outlook 10 years after the third-generation pill scare Contraception 2010;81: 401-7.
52. Grootheest K, Vrieling T. Thromboembolism associated with the new contraceptive Yasmin. BMJ 2003;326: 257. (Pubitemid 36169591)
53. Seeger JD, Loughlin J, Eng PM, e t al. Risk of thromboembolism in women taking ethinylestradiol/ drospirenone and other oral contraceptives. Obstet Gynecol 2007;110:587-93. (Pubitemid 47359582)
54. Kluft C, Endrikat J, Mulder SM, e t al. A prospective study on the effects on hemostasis of two oral contraceptives containing drospirenone in combination with either 30 or 20 microg ethinyl estradiol and a reference containing desogestrel and 30 microg ethinyl estradiol. Contraception 2006;73:336-43. (Pubitemid 43375090)
55. Franks S, Layton A, Glasier A. Cyproterone acetate/ ethinyl estradiol for acne and hirsutism: Time to revise prescribing policy. Hum Reprod 2008;23:231-2. (Pubitemid 351651255)
56. Committee on Safety of Medicines. Cyproterone acetate (Dianette): Risk of venous thromboembolism (VTE). Curr Prob Pharmacovigil 2002;28:9-10.
57. Van den Heuvel MW, van Bragt AJ, Alnabawy AK, Kaptein MC. Comparison of ethinylestradiol pharmacokinetics in three hormonal contraceptive formulations: The vaginal ring, the transdermal patch and an oral contraceptive. Contraception 2005;72:168-74. (Pubitemid 41133355)
58. Peeters, M. ClinicalTrials.gov. A study to evaluate the exposure of norelgestromin and ethinyl estradiol from commercial lots of EVRA - (a transdermal contraceptive patch manufactured by LOHMANN Therapie- Systeme) and CILEST - (an oral contraceptive). Study ID Number: CR002212. ClinicalTrials.gov Identifi er: NCT00258063, Inform 4-3-2008.
59. Johnson JV, Lowell J, Badger GJ, Rosing J. Effects of oral and transdermal hormonal contraception on vascular risk markers. Obstet Gynecol 2008;111:278-84. (Pubitemid 351653416)
60. Jensen JT, Burke AE, Barnhart KT, e t al. Effects of switching from oral to transdermal or vaginal contrace p tion on markers of thrombosis. Contraception 2008;78: 451-8.
61. Jick SS, Hagberg KW, Hernandez RK, Kaye JA. Postmarketing study of ORTHO EVRA - and levonorgestrel contraceptives containing hormonal contraceptives with 30 mcg of ethinyl estradiol in relation to nonfatal venous thromboembolism. Contraception 2010;81: 16-21.
62. Rosing J, Middeldorp S, Curvers J, e t al. Low-dose oral contraceptives and acquired resistance to activated protein C: A randomised cross-over study. Lancet 1999;354: 2036-40.
63. Tans G, Curvers J, Middeldorp S, e t al. A randomized cross-over study on the effects of levonorgestrel- and desogestrel-containing oral contraceptives on the anticoagulant pathways. Thromb Haemost 2000;84:15-21. (Pubitemid 30433661)
64. The Oral Contraceptive and Haemostasis Study Group. The effects of seven monophasic oral contraceptive regimens on haemostatic variables: conclusions from a large randomized multicenter study. Contraception 2003;67: 173-85.
65. van Rooijen M, Silveira A, Hamsten A, Bremme K. Sex hormone-binding globulin - A surrogate marker for the prothrombotic effects of combined oral contraceptives. Am J Obstet Gynecol 2004;190:332-7. (Pubitemid 38249225)
66. Heinemann LAJ, Kluft C, Spannagl M, Maat MPM. The association between extrinsic activated protein C resistance and venous thromboembolism in women. Contraception 2002;66:297-304. (Pubitemid 35350844)
67. Clarkson TB, Shively CA, Morgan TM, e t al. Oral contraceptives and coronary artery atherosclerosis of cynomolgus monkeys. Obstet. Gynecol. 1990;75:217-22. (Pubitemid 20062237)
68. Bezemer I, van der Meer FJM, Eikenboom JCJ, e t al. The value of family history as a risk indicator for venous thrombosis. Arch Intern Med 2009;169:610-5.
69. Mohllajee AP, Curtis KM, Martins SL, Peterson HB. Does use of hormonal contraceptives among women with thrombogenic mutations increase their risk of venous thromboembolism? A systematic review. Contraception 2006;73:166-78. (Pubitemid 43087766)
70. Renoux C, Dell'Aniello S, Suissa S. Hormone replacement therapy and the risk of venous thromboembolism: A population-based study. J Thromb Haemost 2010;8: 979-86.
71. Farley TM, Meirik O, Poulter NR, e t al. Oral contraceptives and thrombotic diseases: Impact of new epidemiological studies. Contraception 1999;54:193-8.